Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer

Yu Chuen Huang, Cheng Ming Lee, Marcelo Chen, Ming Yi Chung, Yen Hwa Chang, William Ji Shian Huang, Donald Ming Tak Ho, Chin Chen Pan, Tony T. Wu, Stone Yang, Ming Wei Lin, Jer Tsong Hsieh, Yi Ming Arthur Chen

研究成果: 雜誌貢獻文章

43 引文 (Scopus)

摘要

Purpose: Glycine N-methyltransferase (GNMT) affects genetic stability by regulating DNA methylation and interacting with environmental carcinogens. In a previous study, we showed that GNMT acts as a susceptibility gene for hepatocellular carcinoma. Here, we report on our efforts to characterize the haplotypes, loss of heterozygosity (LOH), and expression levels of the GNMT in prostate cancer. Experimental Design: Peripheral blood mononuclear cell DNA collected from 326 prostate cancer patients and 327 age-matched controls was used to determine GNMT haplotypes. Luciferase reporter constructs were used to compare the promoter activity of different GNMT haplotypes. GNMT LOH rates in tumorous specimens were investigated via a comparison with peripheral blood mononuclear cell genotypes. Immunohistochemical staining was used to analyze GNMT expression in tissue specimens collected from 5 normal individuals, 33 benign prostatic hyperplasia patients, and 45 prostate cancer patients. Results: Three major GNMT haplotypes were identified in 92% of the participants: A, 16GAs/DEL/C (58%); B, 10GAs/INS/C (19.9%); and C, 10GAs/INS/T (14.5%). Haplotype C carriers had significantly lower risk for prostate cancer compared with individuals with haplotype A (odds ratio, 0.68; 95% confidence interval, 0.48-0.95). Results from a phenotypic analysis showed that haplotype C exhibited the highest promoter activity (P < 0.05, ANOVA test). In addition, 36.4% (8 of 22) of the prostatic tumor tissues had LOH of the GNMT gene. Immunohistochemical staining results showed abundant GNMT expression in normal prostatic and benign prostatic hyperplasia tissues, whereas it was diminished in 82.2% (37 of 45) of the prostate cancer tissues. Conclusions: Our findings suggest that GNMT is a tumor susceptibility gene for prostate cancer.
原文英語
頁(從 - 到)1412-1420
頁數9
期刊Clinical Cancer Research
13
發行號5
DOIs
出版狀態已發佈 - 三月 1 2007
對外發佈Yes

指紋

Glycine N-Methyltransferase
Loss of Heterozygosity
Haplotypes
Prostatic Neoplasms
Prostatic Hyperplasia
Blood Cells
Environmental Carcinogens
Staining and Labeling
Genes
DNA Methylation
Luciferases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. / Huang, Yu Chuen; Lee, Cheng Ming; Chen, Marcelo; Chung, Ming Yi; Chang, Yen Hwa; Huang, William Ji Shian; Ho, Donald Ming Tak; Pan, Chin Chen; Wu, Tony T.; Yang, Stone; Lin, Ming Wei; Hsieh, Jer Tsong; Chen, Yi Ming Arthur.

於: Clinical Cancer Research, 卷 13, 編號 5, 01.03.2007, p. 1412-1420.

研究成果: 雜誌貢獻文章

Huang, YC, Lee, CM, Chen, M, Chung, MY, Chang, YH, Huang, WJS, Ho, DMT, Pan, CC, Wu, TT, Yang, S, Lin, MW, Hsieh, JT & Chen, YMA 2007, 'Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer', Clinical Cancer Research, 卷 13, 編號 5, 頁 1412-1420. https://doi.org/10.1158/1078-0432.CCR-06-1551
Huang, Yu Chuen ; Lee, Cheng Ming ; Chen, Marcelo ; Chung, Ming Yi ; Chang, Yen Hwa ; Huang, William Ji Shian ; Ho, Donald Ming Tak ; Pan, Chin Chen ; Wu, Tony T. ; Yang, Stone ; Lin, Ming Wei ; Hsieh, Jer Tsong ; Chen, Yi Ming Arthur. / Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. 於: Clinical Cancer Research. 2007 ; 卷 13, 編號 5. 頁 1412-1420.
@article{d306a44b28d04e4f8ded80041513ed9b,
title = "Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer",
abstract = "Purpose: Glycine N-methyltransferase (GNMT) affects genetic stability by regulating DNA methylation and interacting with environmental carcinogens. In a previous study, we showed that GNMT acts as a susceptibility gene for hepatocellular carcinoma. Here, we report on our efforts to characterize the haplotypes, loss of heterozygosity (LOH), and expression levels of the GNMT in prostate cancer. Experimental Design: Peripheral blood mononuclear cell DNA collected from 326 prostate cancer patients and 327 age-matched controls was used to determine GNMT haplotypes. Luciferase reporter constructs were used to compare the promoter activity of different GNMT haplotypes. GNMT LOH rates in tumorous specimens were investigated via a comparison with peripheral blood mononuclear cell genotypes. Immunohistochemical staining was used to analyze GNMT expression in tissue specimens collected from 5 normal individuals, 33 benign prostatic hyperplasia patients, and 45 prostate cancer patients. Results: Three major GNMT haplotypes were identified in 92{\%} of the participants: A, 16GAs/DEL/C (58{\%}); B, 10GAs/INS/C (19.9{\%}); and C, 10GAs/INS/T (14.5{\%}). Haplotype C carriers had significantly lower risk for prostate cancer compared with individuals with haplotype A (odds ratio, 0.68; 95{\%} confidence interval, 0.48-0.95). Results from a phenotypic analysis showed that haplotype C exhibited the highest promoter activity (P < 0.05, ANOVA test). In addition, 36.4{\%} (8 of 22) of the prostatic tumor tissues had LOH of the GNMT gene. Immunohistochemical staining results showed abundant GNMT expression in normal prostatic and benign prostatic hyperplasia tissues, whereas it was diminished in 82.2{\%} (37 of 45) of the prostate cancer tissues. Conclusions: Our findings suggest that GNMT is a tumor susceptibility gene for prostate cancer.",
author = "Huang, {Yu Chuen} and Lee, {Cheng Ming} and Marcelo Chen and Chung, {Ming Yi} and Chang, {Yen Hwa} and Huang, {William Ji Shian} and Ho, {Donald Ming Tak} and Pan, {Chin Chen} and Wu, {Tony T.} and Stone Yang and Lin, {Ming Wei} and Hsieh, {Jer Tsong} and Chen, {Yi Ming Arthur}",
year = "2007",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-06-1551",
language = "English",
volume = "13",
pages = "1412--1420",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer

AU - Huang, Yu Chuen

AU - Lee, Cheng Ming

AU - Chen, Marcelo

AU - Chung, Ming Yi

AU - Chang, Yen Hwa

AU - Huang, William Ji Shian

AU - Ho, Donald Ming Tak

AU - Pan, Chin Chen

AU - Wu, Tony T.

AU - Yang, Stone

AU - Lin, Ming Wei

AU - Hsieh, Jer Tsong

AU - Chen, Yi Ming Arthur

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Purpose: Glycine N-methyltransferase (GNMT) affects genetic stability by regulating DNA methylation and interacting with environmental carcinogens. In a previous study, we showed that GNMT acts as a susceptibility gene for hepatocellular carcinoma. Here, we report on our efforts to characterize the haplotypes, loss of heterozygosity (LOH), and expression levels of the GNMT in prostate cancer. Experimental Design: Peripheral blood mononuclear cell DNA collected from 326 prostate cancer patients and 327 age-matched controls was used to determine GNMT haplotypes. Luciferase reporter constructs were used to compare the promoter activity of different GNMT haplotypes. GNMT LOH rates in tumorous specimens were investigated via a comparison with peripheral blood mononuclear cell genotypes. Immunohistochemical staining was used to analyze GNMT expression in tissue specimens collected from 5 normal individuals, 33 benign prostatic hyperplasia patients, and 45 prostate cancer patients. Results: Three major GNMT haplotypes were identified in 92% of the participants: A, 16GAs/DEL/C (58%); B, 10GAs/INS/C (19.9%); and C, 10GAs/INS/T (14.5%). Haplotype C carriers had significantly lower risk for prostate cancer compared with individuals with haplotype A (odds ratio, 0.68; 95% confidence interval, 0.48-0.95). Results from a phenotypic analysis showed that haplotype C exhibited the highest promoter activity (P < 0.05, ANOVA test). In addition, 36.4% (8 of 22) of the prostatic tumor tissues had LOH of the GNMT gene. Immunohistochemical staining results showed abundant GNMT expression in normal prostatic and benign prostatic hyperplasia tissues, whereas it was diminished in 82.2% (37 of 45) of the prostate cancer tissues. Conclusions: Our findings suggest that GNMT is a tumor susceptibility gene for prostate cancer.

AB - Purpose: Glycine N-methyltransferase (GNMT) affects genetic stability by regulating DNA methylation and interacting with environmental carcinogens. In a previous study, we showed that GNMT acts as a susceptibility gene for hepatocellular carcinoma. Here, we report on our efforts to characterize the haplotypes, loss of heterozygosity (LOH), and expression levels of the GNMT in prostate cancer. Experimental Design: Peripheral blood mononuclear cell DNA collected from 326 prostate cancer patients and 327 age-matched controls was used to determine GNMT haplotypes. Luciferase reporter constructs were used to compare the promoter activity of different GNMT haplotypes. GNMT LOH rates in tumorous specimens were investigated via a comparison with peripheral blood mononuclear cell genotypes. Immunohistochemical staining was used to analyze GNMT expression in tissue specimens collected from 5 normal individuals, 33 benign prostatic hyperplasia patients, and 45 prostate cancer patients. Results: Three major GNMT haplotypes were identified in 92% of the participants: A, 16GAs/DEL/C (58%); B, 10GAs/INS/C (19.9%); and C, 10GAs/INS/T (14.5%). Haplotype C carriers had significantly lower risk for prostate cancer compared with individuals with haplotype A (odds ratio, 0.68; 95% confidence interval, 0.48-0.95). Results from a phenotypic analysis showed that haplotype C exhibited the highest promoter activity (P < 0.05, ANOVA test). In addition, 36.4% (8 of 22) of the prostatic tumor tissues had LOH of the GNMT gene. Immunohistochemical staining results showed abundant GNMT expression in normal prostatic and benign prostatic hyperplasia tissues, whereas it was diminished in 82.2% (37 of 45) of the prostate cancer tissues. Conclusions: Our findings suggest that GNMT is a tumor susceptibility gene for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33947434129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947434129&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1551

DO - 10.1158/1078-0432.CCR-06-1551

M3 - Article

C2 - 17332283

AN - SCOPUS:33947434129

VL - 13

SP - 1412

EP - 1420

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -